Clinical applications of natural killer T cell-based immunotherapy for cancer.
about
C-galactosylceramide: Synthesis and immunologyDefective NKT cell activation by CD1d+ TRAMP prostate tumor cells is corrected by interleukin-12 with α-galactosylceramide.Lymphocytes in cancer development: polarization towards pro-tumor immunityA comprehensive ex vivo functional analysis of human NKT cells reveals production of MIP1-α and MIP1-β, a lack of IL-17, and a Th1-bias in malesAlpha-galactosylceramide as a therapeutic agent for pulmonary Mycobacterium tuberculosis infection.Development of spontaneous anergy in invariant natural killer T cells in a mouse model of dyslipidemia.Induced pluripotency as a potential path towards iNKT cell-mediated cancer immunotherapy.Antigen-specific cytotoxicity by invariant NKT cells in vivo is CD95/CD178-dependent and is correlated with antigenic potencyCytokine-induced killer cells co-cultured with dendritic cells loaded with the protein lysate produced by radiofrequency ablation induce a specific antitumor response.Accumulation of invariant NKT cells with increased IFN-γ production in persistent high-risk HPV-infected high-grade cervical intraepithelial neoplasia.Synthesis and Biological Activities of 5-Thio-α-GalCers.Immunological milieu in the peritoneal cavity at laparotomy for gastric cancerCD1d induction in solid tumor cells by histone deacetylase inhibitors through inhibition of HDAC1/2 and activation of Sp1Invariant natural killer T cells: bridging innate and adaptive immunity.Invariant NKT cells are resistant to circulating CD15+ myeloid-derived suppressor cells in patients with head and neck cancer.Natural killer T cells in health and disease.Expression of CD1c enhances human invariant NKT cell activation by α-GalCer.Markers of innate immune function are associated with vitamin a stores in men.Adoptive immunotherapy mediated by ex vivo expanded natural killer T cells against CD1d-expressing lymphoid neoplasmsNKT cells as an ideal anti-tumor immunotherapeuticThe specialized iNKT cell system recognizes glycolipid antigens and bridges the innate and acquired immune systems with potential applications for cancer therapy.Type I natural killer T cells: naturally born for fighting.Invariant natural killer T cell-based immunotherapy for cancer.Invariant NK T cells: potential for immunotherapeutic targeting with glycolipid antigens.Variation of tumor-infiltrating lymphocytes in human cancers: controversy on clinical significance.The role of natural killer T cells in B cell malignancies.A brief review of clinical trials involving manipulation of invariant NKT cells as a promising approach in future cancer therapies.Blockade of programmed death-1/programmed death ligand pathway enhances the antitumor immunity of human invariant natural killer T cells.Human dendritic cells derived from embryonic stem cells stably modified with CD1d efficiently stimulate antitumor invariant natural killer T cell response.Small cell lung cancer tumour cells induce regulatory T lymphocytes, and patient survival correlates negatively with FOXP3+ cells in tumour infiltrate.Alpha-S-GalCer: synthesis and evaluation for iNKT cell stimulation.T-Bet Mediated Anti-Neoplastic Effects of Dendritic Cell-Cytokine Induced Killer Cells in vitro.Acidification-dependent activation of CD1d-restricted natural killer T cells is intact in cystic fibrosis.Comparison of circadian characteristics for cytotoxic lymphocyte subsets in non-small cell lung cancer patients versus controls.
P2860
Q24625835-8D9EA4BD-3D23-48E6-B7DC-56B10586E3AFQ33622444-24438AC8-FE43-4F32-AEEB-7D67FC6B534EQ33712435-8C3273CA-120F-4E78-B4F6-8E3BF8F167BBQ33748552-2BBC0CAB-8583-45D7-AEF9-5C5AF8D24D83Q34172161-378D1784-0E6C-4E61-93BB-B00B2E9EF611Q34235221-717EDFDA-DC37-4793-852B-B5A63EB794C6Q34275397-4C44776D-550C-4676-9EAE-C45B1A4FF938Q34338958-2F103C5C-5FCE-4D90-B901-28E754E89A92Q35167582-91971ED1-8B30-49D2-90AE-F48236C18343Q35559432-60F8D9B4-AEAA-4B5B-A18B-BCC9275FFA5CQ35559790-C3B3F3D2-C99E-41F3-8E7D-6A944E24DC70Q35872049-F4CB1BB2-F5A5-42D6-807B-956D5702A74FQ36012693-2AD56DC9-8230-43F2-AEB3-F8C923A080F9Q36739848-C3F2DBCF-90C8-4095-96CE-7AF082B82B9CQ36746282-E3780DE6-1693-46E5-98CD-1DF02D80A0C0Q36765720-485C6561-9150-4741-9840-E657A73FDD56Q37040200-63A3325A-E818-45F5-A0FD-C41DED7B706AQ37105753-07A8DE4B-D454-44BE-A027-02DB38924966Q37246757-6B82981A-C274-4AF2-B432-6CB8E1991BB0Q37352756-8C20507D-4EC8-49F4-A9DF-49DD093B38F3Q37621786-E600D33D-0108-4743-B17E-912576C4A632Q37728011-82726CF5-C833-4237-A55D-E9A18EC6EC86Q37773278-69BC87AB-D309-4968-8667-7D45DE0C8636Q37822744-6F6041C7-BC39-43C3-A46E-28FB7143F773Q37945304-AC5F14FA-F30E-4B96-B643-9AE61027D8F4Q38090560-74C65A5F-19FF-4FD3-A692-40ED7C7D017BQ38634685-AB779F94-E879-40FA-AA5D-25C2C2CEFE56Q38955079-E1A818CC-BEC9-45D2-ADBB-AE694882DC2EQ39051569-B5BE4034-0FF5-4862-BE8A-20D8C4C083AFQ39359136-FA2D766E-58F2-4326-8402-84EC435AEAD8Q41763024-44D1157F-C29D-40C0-9DA3-DD682A6D7381Q41968968-1597C623-C2F5-40D7-A229-FCCEE2570661Q48232883-71AEC87E-0800-41A7-81A9-6BE1E766BBD5Q48283444-3B4BA103-78E7-45C8-93C4-0F6310516DED
P2860
Clinical applications of natural killer T cell-based immunotherapy for cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 21 February 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Clinical applications of natural killer T cell-based immunotherapy for cancer.
@en
Clinical applications of natural killer T cell-based immunotherapy for cancer.
@nl
type
label
Clinical applications of natural killer T cell-based immunotherapy for cancer.
@en
Clinical applications of natural killer T cell-based immunotherapy for cancer.
@nl
prefLabel
Clinical applications of natural killer T cell-based immunotherapy for cancer.
@en
Clinical applications of natural killer T cell-based immunotherapy for cancer.
@nl
P2860
P1433
P1476
Clinical applications of natural killer T cell-based immunotherapy for cancer.
@en
P2093
Shinichiro Motohashi
P2860
P304
P356
10.1111/J.1349-7006.2008.00730.X
P577
2008-02-21T00:00:00Z